دورية أكاديمية
Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer.
| العنوان: | Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer. |
|---|---|
| المؤلفون: | Hahn AW; Department of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Siddiqui BA; Department of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Leo J; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA., Dondossola E; Department of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Basham KJ; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA., Miranti CK; Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85721, USA., Frigo DE; Department of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.; Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX 77204, USA.; Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA. |
| المصدر: | Endocrinology [Endocrinology] 2023 Apr 17; Vol. 164 (6). |
| نوع المنشور: | Review; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375040 Publication Model: Print Cited Medium: Internet ISSN: 1945-7170 (Electronic) Linking ISSN: 00137227 NLM ISO Abbreviation: Endocrinology Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017- : New York : Oxford University Press Original Publication: Los Angeles, Calif. : Association for the Study of Internal Secretions, |
| مواضيع طبية MeSH: | Prostatic Neoplasms*/pathology , Prostatic Neoplasms, Castration-Resistant*/metabolism, Humans ; Male ; Androgen Receptor Antagonists ; Bone and Bones/metabolism ; Receptors, Androgen/metabolism ; Tumor Microenvironment |
| مستخلص: | Given the central role of the androgen receptor (AR) in prostate cancer cell biology, AR-targeted therapies have been the backbone of prostate cancer treatment for over 50 years. New data indicate that AR is expressed in additional cell types within the tumor microenvironment. Moreover, targeting AR for the treatment of prostate cancer has established side effects such as bone complications and an increased risk of developing cardiometabolic disease, indicating broader roles for AR. With the advent of novel technologies, such as single-cell approaches and advances in preclinical modeling, AR has been identified to have clinically significant functions in other cell types. In this mini-review, we describe new cancer cell-extrinsic roles for AR within the tumor microenvironment as well as systemic effects that collectively impact prostate cancer progression and patient outcomes. (© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| References: | Cancer Res. 2001 Jan 15;61(2):423-7. (PMID: 11212224) N Engl J Med. 2012 Jun 28;366(26):2443-54. (PMID: 22658127) Nat Rev Clin Oncol. 2014 Jun;11(6):365-76. (PMID: 24840076) Front Genet. 2022 Jan 17;12:673180. (PMID: 35111194) Endocrinology. 1989 Mar;124(3):1576-8. (PMID: 2521824) J Immunol. 2004 Nov 15;173(10):6098-108. (PMID: 15528346) Nature. 2018 Jul;559(7714):363-369. (PMID: 29950727) Oncotarget. 2018 Apr 10;9(27):19100-19114. (PMID: 29721186) J Steroid Biochem Mol Biol. 2014 Sep;143:277-84. (PMID: 24787657) Biomicrofluidics. 2019 Nov 20;13(6):064116. (PMID: 31768202) Endocr J. 1999 Jun;46(3):405-13. (PMID: 10503993) Endocrinology. 1997 Sep;138(9):4013-21. (PMID: 9275093) Clin Cancer Res. 2021 Jun 15;27(12):3360-3369. (PMID: 33568344) Mol Oncol. 2018 Aug;12(8):1308-1323. (PMID: 29808619) Dev Biol. 2005 Feb 15;278(2):396-414. (PMID: 15680359) Adv Exp Med Biol. 2019;1210:185-237. (PMID: 31900911) J Urol. 1998 Nov;160(5):1850-5. (PMID: 9783973) Prostate. 2012 Aug 1;72(11):1239-47. (PMID: 22213030) J Clin Oncol. 2020 Feb 10;38(5):395-405. (PMID: 31774688) Nat Commun. 2022 Nov 2;13(1):6552. (PMID: 36323713) Sci Signal. 2017 May 23;10(480):. (PMID: 28536297) Cancer Res. 2011 Jan 15;71(2):528-37. (PMID: 21098087) Eur Urol. 2014 Apr;65(4):816-24. (PMID: 23453420) Nat Cancer. 2021 Aug;2(8):803-818. (PMID: 35122025) EMBO Mol Med. 2012 Aug;4(8):791-807. (PMID: 22745041) Circulation. 2021 Oct 19;144(16):1295-1307. (PMID: 34459214) Diabetes. 2005 Jun;54(6):1717-25. (PMID: 15919793) Annu Rev Immunol. 2022 Apr 26;40:75-94. (PMID: 34985929) Mol Cell Endocrinol. 2019 Jan 5;479:159-169. (PMID: 30308267) Cancer Res. 2010 Apr 15;70(8):3309-19. (PMID: 20388792) Osteoporos Int. 2019 Jan;30(1):115-125. (PMID: 30324413) J Clin Endocrinol Metab. 2004 Oct;89(10):5245-55. (PMID: 15472231) Cell Rep. 2022 May 24;39(8):110848. (PMID: 35613593) Am J Pathol. 2009 Aug;175(2):489-99. (PMID: 19628766) Oncotarget. 2015 Jun 30;6(18):16135-50. (PMID: 25965833) Prostate. 2000 Sep 1;44(4):334-8. (PMID: 10951499) Prostate. 2009 Jun 1;69(8):799-809. (PMID: 19189305) Cancer Res. 2012 Apr 15;72(8):1975-85. (PMID: 22374980) Front Chem. 2019 Sep 26;7:651. (PMID: 31616657) Endocrinology. 2001 Sep;142(9):3800-8. (PMID: 11517156) Steroids. 2013 Sep;78(9):920-6. (PMID: 23707571) CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40. (PMID: 4625049) J Clin Med. 2019 Jan 18;8(1):. (PMID: 30669289) Prostate. 2018 May;78(7):521-531. (PMID: 29473182) Prostate. 2011 Apr;71(5):517-24. (PMID: 20945497) Nature. 1968 Jul 20;219(5151):277-9. (PMID: 5671431) J Urol. 2002 Jun;167(6):2361-7; discussion 2367. (PMID: 11992038) Nat Med. 2017 May;23(5):551-555. (PMID: 28346412) J Clin Oncol. 2006 Aug 20;24(24):3979-83. (PMID: 16921050) Prostate Cancer Prostatic Dis. 2018 Apr;21(1):113-125. (PMID: 29203894) Cold Spring Harb Perspect Med. 2017 Sep 1;7(9):. (PMID: 28389515) Prostate Cancer Prostatic Dis. 2021 Jun;24(2):290-300. (PMID: 33028943) Endocrinology. 2008 Dec;149(12):6028-36. (PMID: 18703637) Cancer Cell. 2005 Mar;7(3):239-49. (PMID: 15766662) Front Oncol. 2020 Aug 07;10:1381. (PMID: 32850444) Mol Cell Endocrinol. 2015 Aug 15;411:198-206. (PMID: 25958043) Biochem Biophys Res Commun. 1996 Mar 27;220(3):858-63. (PMID: 8607856) BMC Cancer. 2015 Nov 02;15:837. (PMID: 26525985) Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70. (PMID: 11734652) Endocrinology. 2007 May;148(5):2264-72. (PMID: 17317769) Am J Physiol. 1998 Jun;274(6):C1645-52. (PMID: 9611130) Differentiation. 2008 Jul;76(6):578-86. (PMID: 18557761) FASEB J. 2014 Jul;28(7):2979-94. (PMID: 24671706) J Cell Sci. 2010 Jan 15;123(Pt 2):266-76. (PMID: 20048343) Endocr Rev. 2023 Jan 12;44(1):117-141. (PMID: 35709009) Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3589-93. (PMID: 11248122) Eur Urol. 2015 May;67(5):825-36. (PMID: 25097095) Endocr Rev. 2022 Jul 13;43(4):720-742. (PMID: 34791092) Immunol Res. 2001;23(2-3):281-8. (PMID: 11444393) Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12679-84. (PMID: 17652515) Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9887-92. (PMID: 24958858) J Endocrinol. 1969 Dec;45(4):531-41. (PMID: 5366114) Endocrinology. 2003 Nov;144(11):5081-8. (PMID: 12960001) Cancer Immunol Res. 2020 Sep;8(9):1215-1227. (PMID: 32661092) FASEB J. 2008 Aug;22(8):2676-89. (PMID: 18390925) J Bone Miner Res. 2015 Jul;30(7):1138-49. (PMID: 25704845) Prostate. 2012 Mar;72(4):437-49. (PMID: 21739465) Nat Med. 2022 Jan;28(1):144-153. (PMID: 35013615) J Clin Invest. 2001 Dec;108(11):1697-704. (PMID: 11733565) EMBO Mol Med. 2013 Sep;5(9):1383-401. (PMID: 23982944) N Engl J Med. 2005 Jan 13;352(2):154-64. (PMID: 15647578) Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11919-11924. (PMID: 27698113) J Biol Chem. 1995 Jan 13;270(2):837-42. (PMID: 7822319) Med Oncol. 2013;30(3):674. (PMID: 23925662) J Cell Mol Med. 2008 Dec;12(6B):2790-8. (PMID: 18266956) Curr Treat Options Cardiovasc Med. 2017 Aug;19(8):61. (PMID: 28653290) Prostate. 2014 Aug;74(11):1118-31. (PMID: 24913829) Mol Endocrinol. 1992 Dec;6(12):2123-8. (PMID: 1491693) Calcif Tissue Int. 1997 Dec;61(6):464-73. (PMID: 9383273) Stem Cells. 2016 Oct;34(10):2536-2547. (PMID: 27300750) iScience. 2021 Mar 13;24(4):102303. (PMID: 33870126) J Endocrinol. 1998 Jan;156(1):115-25. (PMID: 9496241) J Clin Endocrinol Metab. 2002 Feb;87(2):599-603. (PMID: 11836291) J Biol Chem. 1968 Nov 25;243(22):5953-60. (PMID: 5696629) J Clin Oncol. 2006 Sep 20;24(27):4448-56. (PMID: 16983113) Cells. 2019 Oct 25;8(11):. (PMID: 31731497) Nature. 2022 Jun;606(7915):791-796. (PMID: 35322234) J Clin Oncol. 2012 Sep 10;30(26):3271-6. (PMID: 22649143) Endocrinology. 2010 Nov;151(11):5428-37. (PMID: 20861231) J Am Med Dir Assoc. 2014 Aug;15(8):551-8. (PMID: 24703927) Development. 1999 Aug;126(16):3693-701. (PMID: 10409514) Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13498-503. (PMID: 12370412) Am J Physiol. 1998 Nov;275(5):E864-71. (PMID: 9815007) Mol Endocrinol. 2008 Feb;22(2):273-86. (PMID: 17975021) Urology. 2002 Sep;60(3 Suppl 1):79-85; discussion 86. (PMID: 12231056) PLoS One. 2014 Sep 29;9(9):e107516. (PMID: 25264674) Am J Pathol. 2014 Oct;184(10):2598-607. (PMID: 25088980) J Clin Oncol. 2015 Apr 10;33(11):1243-51. (PMID: 25732167) |
| معلومات مُعتمدة: | P50 CA140388 United States CA NCI NIH HHS; R01 CA254200 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: adipose; androgen receptor; bone; cardiovascular; metabolic syndrome; muscle; prostate cancer; tumor microenvironment |
| المشرفين على المادة: | 0 (Androgen Receptor Antagonists) 0 (Receptors, Androgen) 0 (AR protein, human) |
| تواريخ الأحداث: | Date Created: 20230516 Date Completed: 20230618 Latest Revision: 20240517 |
| رمز التحديث: | 20240517 |
| مُعرف محوري في PubMed: | PMC10413433 |
| DOI: | 10.1210/endocr/bqad078 |
| PMID: | 37192413 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1945-7170 |
|---|---|
| DOI: | 10.1210/endocr/bqad078 |